Funding for this research was provided by:
Swedish Cancer Foundation
Sanming Project of Medicine in Shenzhen (SZSM201412014)
The Swedish Foundation for Higher Education and Cooperation
The Science and Technology Foundation of Shenzhen (JCYJ20170307095620828, JCYJ20160422145718224, JCYJ20170412155231633, JSGG20170414104216477, and JCYJ20150402152130696)
The Shenzhen Urology Minimally Invasive Engineering Centre (GCZX2015043016165448)
The Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis
The Shenzhen Cell Therapy Public Service Platform
Olympia Diagnostics, Inc.
Received: 4 August 2020
Accepted: 30 October 2020
First Online: 1 December 2020
Ethics approval and consent to participate
: The multi-center retrospective urine study was approved by IRB at San Francisco General Hospital (IRB # 15-15816) using archived urine samples obtained from Cooperative Human Tissue Network Southern Division and Indivumed GmbH with appropriate ethical approval and patient consent before urine collection. The multi-center prospective urine study was approved by IRB at Shenzhen People’s Hospital (Study Number P2014-006) to collect fresh urine samples from patients treated at seven hospitals collaborated in the study with informed consent.
: Not applicable.
: Heather Johnson is an employee of Olympia Diagnostics, Inc., and inventor of a pending patent application of prostate cancer diagnostic and prognostic biomarkers. No conflict of interest or financial interest was declared by the other authors.